Indications and uses
helps prevent and reduce: plaque gingivitis
helps prevent and reduce: plaque gingivitis
rinse full strength for 30 seconds with 20 ml (2/3 fluid ounce or 4 teaspoonfuls) morning and night do not swallow
Store at Room Temperature cold weather may cloud this product. Its antiseptic properties are not affected.
Drug Facts
Eucalyptol 0.092%
Menthol 0.042%
Methyl salicylate 0.060%
Thymol 0.064%
Antiplaque/antigingivitis
helps prevent and reduce:
Do not use in children under 12 years of age
Keep out of reach of children. If more than used for rinsing is accidentally swallowed, get medical help or contact a Poison Control Center right away.
water, sorbitol solution, alcohol (21.6%), poloxamer 407, flavor, benzoic acid, stevia rebaudiana leaf/stem extract, sodium benzoate
call toll-free 888-222-0182 or 215-273-8755 (collect)
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Eucalyptol | ACTIVE INGREDIENT | RV6J6604TK | 1 | |
| Menthol | ACTIVE INGREDIENT | L7T10EIP3A | 1 | |
| Methyl Salicylate | ACTIVE INGREDIENT | LAV5U5022Y | 1 | |
| Thymol | ACTIVE INGREDIENT | 3J50XA376E | 1 | |
| Eucalyptol | ACTIVE MOIETY | RV6J6604TK | 1 | |
| Menthol | ACTIVE MOIETY | L7T10EIP3A | 1 | |
| Salicylic Acid | ACTIVE MOIETY | O414PZ4LPZ | 1 | |
| Thymol | ACTIVE MOIETY | 3J50XA376E | 1 | |
| Alcohol | INACTIVE INGREDIENT | 3K9958V90M | 1 | |
| Benzoic Acid | INACTIVE INGREDIENT | 8SKN0B0MIM | 1 | |
| Poloxamer 407 | INACTIVE INGREDIENT | TUF2IVW3M2 | 1 | |
| Sodium Benzoate | INACTIVE INGREDIENT | OJ245FE5EU | 1 | |
| Sorbitol | INACTIVE INGREDIENT | 506T60A25R | 1 | |
| Stevia Rebaudiuna Leaf | INACTIVE INGREDIENT | 6TC6NN0876 | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 42002-446 | 42002-446-72, 42002-446-71 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Eucalyptol | RV6J6604TK | ACTIB |
| MENTHOL, UNSPECIFIED FORM | L7T10EIP3A | ACTIB |
| Methyl Salicylate | LAV5U5022Y | ACTIB |
| Thymol | 3J50XA376E | ACTIB |
| Water | 059QF0KO0R | IACT |
| Sorbitol | 506T60A25R | IACT |
| Alcohol | 3K9958V90M | IACT |
| Poloxamer 407 | TUF2IVW3M2 | IACT |
| Benzoic Acid | 8SKN0B0MIM | IACT |
| Stevia Rebaudiuna Leaf | 6TC6NN0876 | IACT |
| Sodium Benzoate | OJ245FE5EU | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sorbitol | SORBITOL | 506T60A25R | LOTION / TOPICAL | 10.7 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION, SOLUTION / SUBCUTANEOUS | 4.7 %w/v | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SPONGE / TOPICAL | NA | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION / INTRAMUSCULAR | NA | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION/ DROPS / ORAL | 23 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | MOUTHWASH / BUCCAL | NA | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, EXTENDED RELEASE / ORAL | 428 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, ORALLY DISINTEGRATING / ORAL | 7 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / INTRAVENOUS | 4000 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SUPPOSITORY / VAGINAL | 2 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GEL / RECTAL | 406 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 35.75 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| Sorbitol | SORBITOL | 506T60A25R | GUM, CHEWING / BUCCAL | 5110 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SUSPENSION / RECTAL | 0.1 %w/w | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | CREAM / TOPICAL | 0.2 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, FILM COATED / ORAL | 5 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| Sorbitol | SORBITOL | 506T60A25R | SYSTEM / TOPICAL | 6300 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SOLUTION / TOPICAL | 0.1 %w/w | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | SOLUTION / ORAL | 50 mg/5ml | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | CREAM / TOPICAL | 13 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | FILM / BUCCAL | 1 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | PASTE, DENTIFRICE / DENTAL | 14 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | SOLUTION / NASAL | 25 mg/1ml | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / TOPICAL | 2445 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | LOTION / TOPICAL | 25 %w/w | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAVENOUS | 864 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION / SUBCUTANEOUS | 4.7 %w/v | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GEL / DENTAL | 0.08 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | LIQUID / ORAL | 53460 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1.04 %w/v | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | CREAM / TOPICAL | 6 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SUSPENSION / ORAL | 15 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | INJECTION / INTRAVENOUS | 92 %w/v | ||
| Sorbitol | SORBITOL | 506T60A25R | CAPSULE / ORAL | 1111 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GEL / TOPICAL | 5 mg | ||
| Sorbitol | SORBITOL | 506T60A25R | INJECTION / INTRALESIONAL | 45 %w/v | ||
| Alcohol | ALCOHOL | 3K9958V90M | SUSPENSION / ORAL | 681 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAMUSCULAR | 864 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| Alcohol | ALCOHOL | 3K9958V90M | DROPS / ORAL | 210 mg/1ml | ||
| Sorbitol | SORBITOL | 506T60A25R | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | CONCENTRATE / ORAL | 20 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | PASTE, DENTIFRICE / DENTAL | 0.5 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | JELLY / VAGINAL | NA | ||
| Sorbitol | SORBITOL | 506T60A25R | SUSPENSION / RECTAL | 46.18 %w/v | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | GEL / PERIODONTAL | 155 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SPRAY / SUBLINGUAL | 397 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | GEL, METERED / TOPICAL | 541 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | PASTE / DENTAL | 1.8 %w/w | ||
| Sorbitol | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | SUSPENSION / INTRATYMPANIC | 63 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / ORAL | 150.68 mg/1ml | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | LOTION / TOPICAL | 71 mg | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | TABLET / ORAL | 495 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a923d80d-6ade-42f8-885f-8369ae595197 | 1b2d5d7b-5f1d-4537-b25c-d9987de0718c | 2020-09-09 | Warnings | a923d80d-6ade-42f8-885f-8369ae595197 1b2d5d7b-5f1d-4537-b25c-d9987de0718c |
Adverse event summaries are temporarily unavailable. Other product information remains available.